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Changing the Risk Threshold for Surgical Prevention of Ovarian Cancer  
 
Ovarian cancer (OC) remains a lethal disease and a major cause of deaths from gynaecological 
cancer particularly in western countries. Despite advances in treatment, there have been only 
marginal improvements in survival rates over the last 30years. Additionally, the number of OC cases 
in the UK is estimated to increase by 27-45%, which translates to a 15% rise in the incidence rate by 
2035.1 A national OC screening programme is unavailable as this has not yet shown a conclusive 
mortality benefit.2 Hence, primary prevention continues to be the cornerstone in reducing the 
burden of OC and improving health outcomes. This is essential to achieve long term 
transformational change and cost-efficiencies in our health-system. Its importance is amplified by 
current economic restraints, with a ~2.4% funding shortfall reported in the UK National-Health-
Service (NHS).  
 
Risk-reducing salpingo-oophorectomy (RRSO) is the most effective method of preventing OC. It is 
usually feasible as a laparoscopic day-case procedure though an overnight stay may at times be 
needed. This option of surgical prevention has traditionally been offered to high-risk women with 
BRCA1/BRCA2 mutations or those with Lynch syndrome, in whom with lifetime OC-risk ranging from 
10% to 40%. The procedure has been shown to be cost-effective in this patient population.3 In 
BRCA1/BRCA2 carriers RRSO is associated with a 79% reduction in OC-risk (HR=0.21, CI:0.12,0.39)4 
and a reduction in OC and all-cause mortality.5 There is a small 2-4% residual risk of primary 
peritoneal cancer over 20years follow-up.  
 
Amongst average risk women RRSO is associated with a 94% reduced risk of OC (HR=0.06, 
CI:0.02,0.17).6 RRSO could potentially be a cost-effective option for this group of women as well. This 
had not previously been explored. We recently estimated the OC-risk thresholds at which RRSO 
would be cost-effective in pre-menopausal7 and post-menopausal8 women. To do this we used a 
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decision-analytic modelling framework. Our decision analytic modelling shows that pre-menopausal 
RRSO is cost-effective at >4% lifetime OC absolute risk with an incremental cost-effectiveness ratio 
(ICER)= £19536/quality-adjusted life-year (QALY) leading to an averaged >42.7days gain in life-
expectancy, if hormone–replacement-therapy (HRT) compliance is high.7 In postmenopausal women 
>50 years, RRSO is cost-effective at ≥5% lifetime OC-risk levels with an ICER= £15247/QALY and 
increases life-expectancy by an average >29.2days.8 Above these risk levels, RRSO saves more life-
years and QALYs and is highly cost-effective at the National Institute for Care-&-Health Excellence 
(NICE) £20,000-30,000/QALY willingness-to-pay threshold. While the number of days gained in life-
expectancy appear small, it is important to highlight these values are averaged across the 
population, and hence, for the individual woman in whom OC is prevented, this is many fold higher. 
As a comparator, undergoing cervical cancer screening leads to a 11.6-32.4days,9 and colorectal 
cancer screening leads to a 55-91days average gain in life-expectancy.10 These analyses fulfil NICE 
requirements for health-economic decision making and are necessary for assessing the balance of 
costs and consequences for recommending policy changes related to new interventions, such as new 
thresholds for surgical prevention.  
 
It is estimated that around 9% of the UK population has an OC-risk ≥5%, and this group accounts for 
53% of OC cases, while 13.4% of the population is at >4% risk and 62.8% OC cases occur in them.11 
The availability of data supporting surgical prevention at intermediate 5%-10% levels of OC-risk 
provides a significant opportunity to reduce OC incidence and make a much greater impact on 
burden of this fatal disease. Genetic testing for more recently identified moderate-risk OC genes 
RAD51C, RAD51D and BRIP1, is now clinically available. Mutations in these genes are associated with 
lifetime risks in the range 5.8% to 11%, although confidence intervals are wide.  As more data 
accumulate, the precision of these estimates will improve and CIs narrow. We feel RRSO should be 
made available to unaffected women with these moderate penetrance mutations who have 
completed their family after proper counselling. OC has not yet been reported under 40years age in 
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RAD51C and RAD51D carriers or under 50 years in BRIP1 carriers. Hence, surgical prevention is best 
delayed till >40 or >50years in these women respectively. First-degree-relatives of women with OC 
and BRCA1/BRCA2 negative women (without a known pathogenic mutation in the family) but with a 
strong family history of OC or OC ‘and’ breast cancer (BC) are also at intermediate-risk and could 
qualify for surgical prevention. In intermediate-risk women with no gene mutation we would suggest 
RRSO after 50 or the menopause. 
 
We recently published OC-risk models which can identify women at these intermediate-risk 
thresholds.11, 12 Incorporating SNPs/common genetic-variants into models permit more accurate risk 
prediction. Three quarters of the familial relative risk for OC is not accounted for by BRCA mutations 
and using a SNP based polygenic-risk-score in combination with family-history can identify women 
above the 5% risk threshold and improve risk prediction in BRCA negative women.11  Using a 
combination of known OC risk factors of endometriosis, tubal ligation, parity, contraceptive pill, and 
family history (first-degree-relative with OC) along with SNP profile, it is possible to identify eight 
categories with a ≥5% life time OC-risk.12 The authors estimated that 2% of women in the USA would 
be at ≥5% lifetime OC-risk.12  
 
More sophisticated models incorporating epidemiological data, next generation sequencing driven 
panel-testing, moderate penetrance genes, and increasing number of OC SNPs are under 
development within the PROMISE (Predicting-Risk of Ovarian-Malignancy Improved-Screening & 
Early-detection) programme and OCAC (Ovarian Cancer Action Consortium). As these models get 
validated and made available, the capability to predict risk will increase and its clinical application 
will expand even more in the near future. Going forward, it could provide a potential opportunity for 
population-based risk stratification for OC for the purpose of targeted surgical prevention. A pilot 
study to assess feasibility of such an approach will commence in summer of 2017.  
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Limitations: 
While acceptability of RRSO for high penetrance gene mutations is well established with uptake 
rates of up to 70% reported, the acceptability and uptake at intermediate-risk thresholds is unknown 
as RRSO was not previously available at these levels. The risk of surgical complications from RRSO is 
around 3% and needs to be an important part of informed decision making on whether to undergo 
the procedure. Another important issue for women undergoing premenopausal oophorectomy is 
the detrimental consequences of premature surgical menopause. It is associated with osteoporosis, 
vasomotor symptoms, increased risk of cardiovascular-disease, and detrimental impact on sexual-
function. An absolute increase in cardiovascular mortality of 3.03% has been described in women 
who do not take HRT.6 The harmful side effects can be ameliorated by HRT and are seen 
predominantly in women <45 years who decline or are unable to have HRT. Studies suggest that 
some of the protective neurocognitive effects may not however be fully addressed by HRT. Short 
term HRT given till the age of 50years following premature surgical menopause has not been shown 
increase BC-risk . The importance of these issues in decision making is well documented in high-risk 
women, such as BRCA1/BRCA2 carriers as a number of them delay RRSO till after menopause. 
Despite the downsides, high satisfaction rates of >85% are reported with RRSO in BRCA1/BRCA2 
carriers. Corresponding data for intermediate-risk women is not available.  
 
Role of Hysterectomy:  
The utility of concomitant hysterectomy as part of the surgical procedure with RRSO to prevent OC 
has been debated. Practice varies in different parts of the world, with hysterectomy more prevalent 
in some countries like USA, Australia.  In a number of these countries, a significant proportion of 
medical practice is private and insurance driven which may also influence differences in approach. 
Proponents of a concurrent hysterectomy cite the benefits of estrogen alone HRT and avoiding 
cervical smears. Hysterectomy is a major operation with significantly higher morbidity, longer 
operating time, hospital stay and recovery than bilateral salpingo-oophorectomy. We and most UK 
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centres don’t routinely undertake hysterectomy for OC prevention in high-risk women, for a number 
of reasons. Hysterectomy is not routinely offered as an alternate to progesterone component of HRT 
in gynaecological practice. The large number of women on HRT attending routine gynaecological 
menopause clinics are not offered this. Short-term HRT given in this context till the average age of 
menopause (51years) does not increase BC-risk.13 Mirena-IUS (intra-uterine-progestogen coil) with 
minimal systemic absorption can be used for the progestogenic component of HRT. While one 
recent report suggests the relative-risk of ‘serous’ endometrial-cancer (EC) may be increased in 
BRCA1 women,14 corroborating studies are awaited. Additionally serous-subtype comprises a very 
small proportion (~6.5%) of ECs and the overall EC-risk is not significantly increased in BRCA1 
women. Hence, it’s not currently our practice to routinely offer this. Premenopausal BRCA/high-risk 
women with ER+ BC on Tamoxifen, have a ~2-3 fold increased risk of endometrioid EC. However, the 
absolute EC-risk is still very low (2.3cases/1000 women/year-of-use),15 with a favourable risk profile 
in pre-menopausal women and increased EC-risk reported in women ≥50years.15We do not feel this 
risk justifies routine hysterectomy but any unscheduled/abnormal bleeding promptly investigated. 
This is consistent with ACOG and RCOG guidelines on Tamoxifen. One clear exception is Lynch-
Syndrome women (lifetime EC-risk ~40%), in whom hysterectomy is undertaken for surgical 
prevention. 
 
Salpingectomy in high-risk women: 
The increasing acceptance of the tubal origin of OC has led to premenopausal Early-Salpingectomy 
(ES) followed by delayed-oophorectomy (DO) at menopause, proposed as a two-step OC prevention 
strategy for high-risk women. This enables women to obtain some OC-risk reduction while averting 
detrimental consequences of premature menopause. However, prospective data are lacking for (a) 
long-term endocrine function and menopause onset, (b) precise level of OC-risk reduction obtained, 
(c) quality-of-life, (d) psychosocial impact. Concerns have also been expressed regarding long-term 
follow-up and attrition from DO. Some of them may develop OC and this procedure will have been a 
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failure.16 While 70% occult insitu/invasive lesions identified at RRSO in BRCA1/BRCA2 women are 
tubal 30% are not.17 Our understanding of the roles and interaction of the tube-&-ovary in OC 
etiopathogenesis is still incomplete and evolving. Not all STIC (serous-tubal-intraepithelial-
carcinomas) are precursors of OC and some may be metastatic.18 Only up to 61% OCs have STICs 
associated with them. Salpingectomy will therefore not prevent all OC. Surgico-pathological 
protocols for undertaking ES and managing occult lesions need standardisation and utility-scores 
required for health-economic analysis need developing. Given limitations highlighted above, their 
remains significant uncertainty around the cost-effectiveness of an ES-strategy. It is best that ES-&-
DO is evaluated/undertaken within the safe environment of a clinical trial not routine practice. 
Salpingectomy studies are underway in France (Radical-Fimbriectomy-study NCT01608074), USA 
(MD Anderson: NCT01907789), The Netherlands (TUBA-study NCT02321228). A UK-study 
(PROTECTOR) will commence later this year.   
 
The contraceptive pill:  
There is good evidence to show that oral contraceptive pill (OCP) use significantly reduces OC-risk in 
average-risk women.19 The level of risk-reduction increases with duration of use and, benefits persist 
for 30years after stopping the pill. The risk-reduction obtained is 22% with 1-4 years use, 35% after 
5-9 years use, 45% with 10-14 years and 58% with ≥15 years use.19  Data from high-risk populations 
suggest similar benefits are found in BRCA1/BRCA2 carriers, with 5-years’ OCP use halving the OC-
risk (risk-reduction ranges from 33%-80% in BRCA1, 58%-63% in BRCA2).20 Although specific data for 
intermediate-risk women is lacking, OCP-use is likely to provide similar benefits to them too. A 
disadvantage is an increased BC-risk in average-risk women (RR=1.24, CI:1.15,1.33) and for up to 
10years after stopping the pill. However, the absolute increase in BC-risk is small. OCP is 
contraindicated in women who have had BC but not in those with a family-history of BC. Studies 
evaluating the impact of OCP on BC-risk in BRCA1/BRCA2 carriers show conflicting results.  Meta-
analysis from case-control data show no increase in BC-risk (BRCA1 ES=0.78, CI:0.59-1.04; BRCA2 
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ES=1.04, CI:0.81-1.32),20 but, cohort data report an increased BC-risk (BRCA1 ES=1.59, CI:1.32-1.92; 
BRCA2 ES=1.85, CI:1.30-2.64).20 The absolute increase in risk is probably small if taken at a young 
age. Progesterone-only-pill, implants and injectable contraception may be safer options.  
 
The OC-risk threshold for surgical prevention has previously been set too high. We call for a review 
of this threshold. Changing this to around the 5% life-time risk level provides an important cost-
effective strategy for OC prevention. Widening access to RRSO will also require the need for health 
professionals to ensure that women who undergo premenopausal oophorectomy appreciate the 
importance and need for HRT till the age of natural menopause. A mechanism of ensuring 
compliance which includes sustained access to prescriptions and long term monitoring will be 
needed. Health service capacity issues including expansion in downstream management pathways 
will need to be addressed. The rising costs of OC drugs and treatment, persistent poor survival 
outcomes, lack of effective screening programme and predicted increase in burden of disease, 
emphasise the need for shifting focus towards better targeted cost-effective prevention. It is 
important we seize this opportunity afforded to maximise prevention of this devastating disease. 
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